Regeneron and Intellia expand CRISPR collaboration to neurological and muscular diseases

Intellia Therapeutics, Inc.

Uses Regeneron's antibody-targeted AAV vectors and Intellia's Nme2CRISPR/Cas9 for in vivo delivery.
Initial research on two non-liver targets for neurological and muscular diseases.
Each company may lead development/commercialization for one target; co-development option available.
Builds on existing successful collaboration between the two firms.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.